Cover Image

PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma

Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that lacks durable responses to traditional chemotherapy.Areas covered: After MCC was shown to be an immunogenic tumor, small trials revealed high objective response rates to PD-1/PD-L1 checkpoint inhibitor...

Full description

Saved in:
Bibliographic Details
Main Authors: Gaiser, Maria (Author) , Bongiorno, Michelle (Author) , Brownell, Isaac (Author)
Format: Article (Journal)
Language:English
Published: 14 Mar 2018
In: Expert review of clinical pharmacology
Year: 2018, Volume: 11, Issue: 4, Pages: 345-359
ISSN:1751-2441
DOI:10.1080/17512433.2018.1445966
Online Access:Verlag, Volltext: https://doi.org/10.1080/17512433.2018.1445966
Get full text
Author Notes:Maria Rita Gaiser, Michelle Bongiorno, Isaac Brownell

MARC

LEADER 00000caa a2200000 c 4500
001 1671028872
003 DE-627
005 20230428190732.0
007 cr uuu---uuuuu
008 190808s2018 xx |||||o 00| ||eng c
024 7 |a 10.1080/17512433.2018.1445966  |2 doi 
035 |a (DE-627)1671028872 
035 |a (DE-599)KXP1671028872 
035 |a (OCoLC)1341235642 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Gaiser, Maria  |d 1979-  |e VerfasserIn  |0 (DE-588)1074971930  |0 (DE-627)832793035  |0 (DE-576)443175551  |4 aut 
245 1 0 |a PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma  |c Maria Rita Gaiser, Michelle Bongiorno, Isaac Brownell 
264 1 |c 14 Mar 2018 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 08.08.2019 
520 |a Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that lacks durable responses to traditional chemotherapy.Areas covered: After MCC was shown to be an immunogenic tumor, small trials revealed high objective response rates to PD-1/PD-L1 checkpoint inhibitors. The JAVELIN Merkel 200 (NCT02155647) trial tested the use of avelumab, a human IgG1 monoclonal antibody against PD-L1, in metastatic MCC. Avelumab recently became the first approved drug for metastatic MCC.Expert commentary: By conducting broad phase I studies assessing the safety of avelumab and a small phase II study demonstrating efficacy in this rare orphan tumor type, avelumab gained accelerated approval for the treatment of metastatic MCC. Additional studies are needed to determine how the antibody-dependent cellular cytotoxicity (ADCC) competent Fc region of avelumab contributes to disease control.Remaining questions: Longer follow-up will determine the durability of checkpoint blockade in controlling metastatic MCC. Additional studies will assess the utility and safety of adjuvant checkpoint blockade in patients with excised MCC. How to increase response rates by combining PD-1/PD-L1 blockade with other treatment approaches needs to be explored. In addition, treatment options for MCC patients who fail or do not respond to avelumab need to be identified. 
650 4 |a Anti-PD-1 
650 4 |a anti-PD-L1 
650 4 |a avelumab 
650 4 |a Bavencio 
650 4 |a checkpoint inhibitor 
650 4 |a immunotherapy 
650 4 |a Merkel cell carcinoma 
650 4 |a pembrolizumab 
700 1 |a Bongiorno, Michelle  |e VerfasserIn  |0 (DE-588)1192481852  |0 (DE-627)1671023110  |4 aut 
700 1 |a Brownell, Isaac  |e VerfasserIn  |0 (DE-588)1192482255  |0 (DE-627)1671025032  |4 aut 
773 0 8 |i Enthalten in  |t Expert review of clinical pharmacology  |d London : Informa Healthcare, 2008  |g 11(2018), 4, Seite 345-359  |h Online-Ressource  |w (DE-627)600591751  |w (DE-600)2495954-6  |w (DE-576)398101086  |x 1751-2441  |7 nnas  |a PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma 
773 1 8 |g volume:11  |g year:2018  |g number:4  |g pages:345-359  |g extent:15  |a PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma 
856 4 0 |u https://doi.org/10.1080/17512433.2018.1445966  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20190808 
993 |a Article 
994 |a 2018 
998 |g 1074971930  |a Gaiser, Maria  |m 1074971930:Gaiser, Maria  |d 60000  |d 61900  |e 60000PG1074971930  |e 61900PG1074971930  |k 0/60000/  |k 1/60000/61900/  |p 1  |x j 
999 |a KXP-PPN1671028872  |e 3505887269 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"note":["Gesehen am 01.09.15"],"title":[{"title":"Expert review of clinical pharmacology","title_sort":"Expert review of clinical pharmacology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"2008","publisherPlace":"London ; London","dateIssuedDisp":"2008-","publisher":"Informa Healthcare ; Expert Reviews Ltd"}],"pubHistory":["1.2008 -"],"language":["eng"],"id":{"zdb":["2495954-6"],"eki":["600591751"],"issn":["1751-2441"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"PD-L1 inhibition with avelumab for metastatic Merkel cell carcinomaExpert review of clinical pharmacology","part":{"pages":"345-359","year":"2018","extent":"15","text":"11(2018), 4, Seite 345-359","issue":"4","volume":"11"},"recId":"600591751"}],"person":[{"given":"Maria","family":"Gaiser","display":"Gaiser, Maria","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Bongiorno","given":"Michelle","display":"Bongiorno, Michelle","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Brownell, Isaac","family":"Brownell","given":"Isaac"}],"name":{"displayForm":["Maria Rita Gaiser, Michelle Bongiorno, Isaac Brownell"]},"recId":"1671028872","title":[{"title_sort":"PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma","title":"PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma"}],"language":["eng"],"origin":[{"dateIssuedDisp":"14 Mar 2018","dateIssuedKey":"2018"}],"id":{"eki":["1671028872"],"doi":["10.1080/17512433.2018.1445966"]},"note":["Gesehen am 08.08.2019"],"physDesc":[{"extent":"15 S."}]} 
SRT |a GAISERMARIPDL1INHIBI1420 

Similar Items